This brand name is authorized in Austria, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Israel, Lithuania, Malta, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Turkey, UK.
The drug VARILRIX contains one active pharmaceutical ingredient (API):
1
|
UNII
GPV39ZGD8C - VARICELLA-ZOSTER VIRUS STRAIN OKA/MERCK LIVE ANTIGEN
|
|
Natural infection induces a cellular and humoral immune response to the varicella-zoster virus, which can be rapidly detected following infection. IgG, IgM and IgA directed against viral proteins usually appear at the same time that a cellular immune response can be demonstrated, making the relative contribution of humoral and cellular immunity to disease progression difficult to ascertain. Vaccination has been shown to induce both humoral and cell-mediated types of immunity. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| VARILRIX Powder and solvent for solution for injection | MPI, EU: SmPC | Medicines & Healthcare Products Regulatory Agency (GB) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| J07BK01 | Varicella, live attenuated | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BK Varicella zoster vaccines |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| BR | Câmara de Regulação do Mercado de Medicamentos | 510608501157316, 510618090060407, 510620060055307 |
| CA | Health Products and Food Branch | 02241047 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 157-MBE-0620, 22.061-1-05-05 |
| EE | Ravimiamet | 1027998, 1847774 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 169664 |
| FR | Base de données publique des médicaments | 62521070 |
| GB | Medicines & Healthcare Products Regulatory Agency | 46230 |
| HK | Department of Health Drug Office | 41798 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 4200 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1010804, 1057589 |
| MT | Medicines Authority | MA170/00801, MA170/00802, PI1438/03001A |
| NG | Registered Drug Product Database | A6-0190 |
| NZ | Medicines and Medical Devices Safety Authority | 4857 |
| PL | Rejestru Produktów Leczniczych | 100092252 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W55459001, W55459002, W55459003, W55459004, W55459005, W55459006, W55459007, W55459008, W55459009, W55459010, W55459011, W55459012, W55459013, W55459014, W55459015, W55459016, W55459017, W55459018 |
| SG | Health Sciences Authority | 09001P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699522967452 |
| ZA | Health Products Regulatory Authority | 32/30.1/0468 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.